Shelton Capital Management boosted its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 24.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,826 shares of the medical instruments supplier’s stock after buying an additional 4,500 shares during the period. Shelton Capital Management’s holdings in OraSure Technologies were worth $430,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Oppenheimer Asset Management Inc. bought a new position in shares of OraSure Technologies during the 3rd quarter worth approximately $186,000. ARP Americas LLC bought a new position in shares of OraSure Technologies during the 3rd quarter worth approximately $221,000. Noesis Capital Mangement Corp bought a new position in shares of OraSure Technologies during the 3rd quarter worth approximately $225,000. Profund Advisors LLC grew its stake in shares of OraSure Technologies by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 293 shares in the last quarter. Finally, Shikiar Asset Management Inc. bought a new position in shares of OraSure Technologies during the 4th quarter worth approximately $207,000. 92.29% of the stock is owned by institutional investors.

OraSure Technologies, Inc. (OSUR) opened at $18.00 on Friday. The firm has a market cap of $1,091.66, a P/E ratio of 35.29, a PEG ratio of 4.00 and a beta of 1.43. OraSure Technologies, Inc. has a 52 week low of $9.92 and a 52 week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The company had revenue of $52.00 million during the quarter, compared to analysts’ expectations of $50.20 million. During the same period last year, the business earned $0.13 EPS. The business’s quarterly revenue was up 46.5% on a year-over-year basis. equities analysts predict that OraSure Technologies, Inc. will post 0.31 EPS for the current year.

OSUR has been the subject of several research reports. Jefferies Group reaffirmed a “buy” rating and set a $23.00 price target on shares of OraSure Technologies in a research note on Friday, October 20th. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Wednesday, October 25th. ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BidaskClub raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $24.00 price target on shares of OraSure Technologies in a research note on Friday, February 2nd. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. OraSure Technologies currently has an average rating of “Buy” and a consensus target price of $22.25.

ILLEGAL ACTIVITY WARNING: “OraSure Technologies, Inc. (OSUR) Shares Bought by Shelton Capital Management” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/11/orasure-technologies-inc-osur-shares-bought-by-shelton-capital-management.html.

OraSure Technologies Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.